GB2355194B - Coformulation methods and their products - Google Patents

Coformulation methods and their products

Info

Publication number
GB2355194B
GB2355194B GB0021227A GB0021227A GB2355194B GB 2355194 B GB2355194 B GB 2355194B GB 0021227 A GB0021227 A GB 0021227A GB 0021227 A GB0021227 A GB 0021227A GB 2355194 B GB2355194 B GB 2355194B
Authority
GB
United Kingdom
Prior art keywords
coformulation
products
methods
coformulation methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0021227A
Other versions
GB2355194A (en
GB0021227D0 (en
Inventor
Richard Anthony Storey
Stephen Ernest Walker
Simon Anthony Wilkins
Peter York
Ronald Scott Harland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics UK Ltd
Bristol Myers Squibb Co
Original Assignee
Bradford Particle Design Ltd
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bradford Particle Design Ltd, Bristol Myers Squibb Co filed Critical Bradford Particle Design Ltd
Priority to GB0220996A priority Critical patent/GB2381453A/en
Publication of GB0021227D0 publication Critical patent/GB0021227D0/en
Publication of GB2355194A publication Critical patent/GB2355194A/en
Application granted granted Critical
Publication of GB2355194B publication Critical patent/GB2355194B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0407—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solute
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0488—Flow sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB0021227A 1999-08-31 2000-08-31 Coformulation methods and their products Expired - Fee Related GB2355194B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0220996A GB2381453A (en) 1999-08-31 2000-08-31 Active/polymer coformulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9920558.5A GB9920558D0 (en) 1999-08-31 1999-08-31 Methods for particle formation and their products

Publications (3)

Publication Number Publication Date
GB0021227D0 GB0021227D0 (en) 2000-10-18
GB2355194A GB2355194A (en) 2001-04-18
GB2355194B true GB2355194B (en) 2003-01-08

Family

ID=10860085

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9920558.5A Ceased GB9920558D0 (en) 1999-08-31 1999-08-31 Methods for particle formation and their products
GB0021227A Expired - Fee Related GB2355194B (en) 1999-08-31 2000-08-31 Coformulation methods and their products

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB9920558.5A Ceased GB9920558D0 (en) 1999-08-31 1999-08-31 Methods for particle formation and their products

Country Status (8)

Country Link
EP (1) EP1207856A2 (en)
JP (1) JP2003508419A (en)
KR (1) KR20020047137A (en)
AU (1) AU783570B2 (en)
CA (1) CA2382556A1 (en)
GB (2) GB9920558D0 (en)
MX (1) MXPA02001803A (en)
WO (1) WO2001015664A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144761A0 (en) 1999-12-08 2002-08-14 Pharmacia Corp Solid-state form of celecoxib having enhanced bioavailability
CH694686A5 (en) 2000-03-04 2005-06-15 Eco2 Sa Product micronization of pharmaceutical substances.
FR2815540B1 (en) † 2000-10-19 2005-06-10 Separex Sa PROCESS FOR MANUFACTURING VERY FINE PARTICLES COMPRISING A PRINCIPLE INSERTED IN A HOST MOLECULE
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
DE60226140T2 (en) 2001-05-30 2009-05-07 Csir, Pretoria METHOD FOR THE SECULATION OF AN ACTIVE SUBSTANCE
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
ES2333645T3 (en) 2001-06-22 2010-02-25 Bend Research, Inc. PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF MEDICINES AND NEUTRAL POLYMERS.
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CA2464308A1 (en) 2001-10-22 2003-05-01 Dompe S.P.A. Supercritical fluids processing: preparation of protein microparticles and their stabilisation
ATE401058T1 (en) 2001-11-01 2008-08-15 Nektar Therapeutics SPRAY DRYING METHOD
ATE395044T1 (en) 2002-02-01 2008-05-15 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHIC DISPERSIONS OF ACTIVE INGREDIENTS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
BRPI0409962A (en) 2003-05-08 2006-04-25 Nektar Therapeutics Uk Ltd particulate co-formulation of an active substance and an excipient, pharmaceutical or nutritional composition, pharmaceutical or nutritional product, method for preparing a particulate co-formulation of an active substance and an excipient, and use of an active substance and an excipient
ATE540671T1 (en) 2003-08-04 2012-01-15 Bend Res Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DRUG ADSORBATES AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
EP2077823B1 (en) 2006-10-11 2012-06-27 Crititech, Inc. Method for precipitation of small medicament particles into use containers
GB0702402D0 (en) 2007-02-08 2007-03-21 Thar Pharmaceuticals Inc Method of creating crystalline substances
CN101677954A (en) 2007-02-11 2010-03-24 Map药物公司 Therapeutic administration DHE is used for alleviating migraine fast and makes the side effect minimized method that distributes
PL2229233T3 (en) 2007-12-07 2020-03-31 Xspray Pharma Ab (Publ) Method for the production of particles
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
JP6238311B2 (en) * 2012-01-13 2017-11-29 エックススプレイ ファーマ パブリーク・アクチエボラグＸＳｐｒａｙ Ｐｈａｒｍａ ＡＢ（ｐｕｂｌ） Pharmaceutical composition comprising stable amorphous hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing matrix-forming component
ES2854751T3 (en) * 2012-01-13 2021-09-22 Xspray Microparticles Ab A process for producing stable amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one matrix-forming and stabilizing polymer component

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2053681A (en) * 1979-07-05 1981-02-11 Yamanouchi Pharma Co Ltd Sustained release pharmaceutical composition
EP0462066A1 (en) * 1990-06-15 1991-12-18 Warner-Lambert Company Amorphous gemfibrozil
WO1996036318A2 (en) * 1995-05-19 1996-11-21 Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov,D.D. Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
WO1997039050A1 (en) * 1996-04-18 1997-10-23 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems - amorphous drugs
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
WO1999059541A2 (en) * 1998-05-15 1999-11-25 Basf Aktiengesellschaft Cyclosporin preparations
WO2000072825A1 (en) * 1999-05-29 2000-12-07 Abbott Laboratories Novel formulations comprising lipid-regulating agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4041563A1 (en) * 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh METHOD FOR PRODUCING ACTIVE MICROPARTICLES FROM HYDROLYTICALLY DEGRADABLE POLYMERS
IT1255792B (en) * 1992-08-05 1995-11-16 Bayer Italia Spa PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ADMINISTRATION OF DIHYDROPYRIDINS IN THE FORM OF DRINK
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
EP0885038B1 (en) * 1996-03-01 2011-06-15 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
CA2254061C (en) * 1996-05-17 2003-12-02 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
FR2753639B1 (en) * 1996-09-25 1998-12-11 PROCESS FOR THE PREPARATION OF MICROCAPSULES OF ACTIVE MATERIALS COATED WITH A POLYMER AND NOVEL MICROCAPSULES OBTAINED IN PARTICULAR BY THE PROCESS
IT1296464B1 (en) * 1997-11-19 1999-06-25 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF DRUG-LOADED CROSS-LINKED POLYMER POWDERS AND RELATED PREPARATION PROCESS BY MEANS
GB9915975D0 (en) * 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2053681A (en) * 1979-07-05 1981-02-11 Yamanouchi Pharma Co Ltd Sustained release pharmaceutical composition
EP0462066A1 (en) * 1990-06-15 1991-12-18 Warner-Lambert Company Amorphous gemfibrozil
WO1996036318A2 (en) * 1995-05-19 1996-11-21 Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov,D.D. Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
WO1997039050A1 (en) * 1996-04-18 1997-10-23 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems - amorphous drugs
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
WO1999059541A2 (en) * 1998-05-15 1999-11-25 Basf Aktiengesellschaft Cyclosporin preparations
WO2000072825A1 (en) * 1999-05-29 2000-12-07 Abbott Laboratories Novel formulations comprising lipid-regulating agents

Also Published As

Publication number Publication date
MXPA02001803A (en) 2004-02-26
GB9920558D0 (en) 1999-11-03
AU6855000A (en) 2001-03-26
AU783570B2 (en) 2005-11-10
JP2003508419A (en) 2003-03-04
KR20020047137A (en) 2002-06-21
CA2382556A1 (en) 2001-03-08
GB2355194A (en) 2001-04-18
WO2001015664A3 (en) 2001-09-20
EP1207856A2 (en) 2002-05-29
WO2001015664A2 (en) 2001-03-08
GB0021227D0 (en) 2000-10-18

Similar Documents

Publication Publication Date Title
GB2355194B (en) Coformulation methods and their products
AU6503299A (en) High-beta-conglycinin products and their use
HUP0302495A3 (en) Methods and devices foranalyzing agricultural products
HRP20060251B1 (en) Substituted oxasolidinones and their use
AP2001002227A0 (en) Colapsible crate and associated connecting means
EP1198184A4 (en) Appliqu method and article
GB9906009D0 (en) Product
EP1347866A4 (en) Wood products and processes for the preparation thereof
PL355542A1 (en) Energy food product
PL353803A1 (en) Radiopharmaceutical products and their preparation procedure
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
GB9927474D0 (en) Food product
HUP0202304A3 (en) Food product
HUP0000042A3 (en) Omega-3-fatacid and vitamin containing meet product
GB9928490D0 (en) Products and processes therefor
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
EP1194147A4 (en) Arylthiazolidinedione and aryloxazolidinedione derivatives
GB0020179D0 (en) Kaolin products and their use
AU1064800A (en) Products and methods
EP1229913A4 (en) Substituted 1-benzazepines and derivatives thereof
GB9910823D0 (en) Containers for cosmetic products and the like
HK1048418A1 (en) Smoking products
AU7023300A (en) Product and method
GB9914202D0 (en) Products and methods
GB9912059D0 (en) Products and methods

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20070831